The University of Maryland, Baltimores (UMB) Office of Technology Transfer has completed a license agreement with Bali BioSciences LLC, an early-stage company pursuing an unusual, yet clever, strategy to combat disease.
The company, together with its affiliated operating company Bali Medical Inc., is developing a medical food product as adjunctive therapy for patients with burn- and trauma-related sepsis, HIV/AIDS, and other endotoxin-mediated diseases.
"Our concept is to vaccinate dairy cows with an anti-sepsis vaccine and harvest colostrum [immune milk] that is enriched with highly specific yet broadly cross-reactive antibodies against endotoxin. The enhanced colostrum-based product will aid patients by reducing the nutritional deficits associated with burns, trauma, and HIV/AIDS," says Bali BioSciences CEO and founder Zeil Rosenberg, MD, MPH.
A specialized anti-sepsis vaccine was developed by Alan Cross, MD, a professor at the University of Maryland School of Medicine, and his colleagues at the Walter Reed Army Institute of Research, and Memorial Hospital of Rhode Island.
The vaccine has already proven safe in human trials, and showed protective efficacy in various animal models. Thus, it has potential for use in both prevention and treatment of sepsis. UMB technology transfer officials completed a royalty-bearing license for the jointly owned technology and related patent rights to Bali BioSciences. There are also plans for a sponsored research collaboration to tap into Cross considerable expertise to aid the companys early research and development efforts.
There are more than 33 million people worldwide living with HIV, which constitutes a significant population in need of adjunctive nutritional therapy. "Bali BioSciences will help address that need with its affordable medical food product," says James L. Hughes, MBA, vice president for research and development at UMB.
Cross is a physician with 35 years of research experience in the fields of inflammation and infectious disease and is the author of 173 peer-reviewed publications. His numerous professional honors include the U.S. Armys Legion of Merit in 1994, service as president of the International Endotoxin and Innate Immunity Society from 2008 to 2010, and multiple advisory committee memberships over the past decade for the FDA, NIH, and the National Academy of Sciences.
Rosenberg is a physician-executive with 25 years experience in management of domestic and international health issues, including immunization programs and pediatric infectious diseases. He was previously CEO of Immuron Ltd. and served for eight years as Becton Dickinsons worldwide business leader and medical director for immunization.
UMB has a portfolio of hundreds of technologies available for licensing that are a mix of vaccines, drug targets, therapeutics, devices, and cutting-edge techniques that promise to make a quantifiable impact on human health and the environment. The internationally recognized medical, dental, and pharmaceutical research underway at UMB provides a robust pipeline of more than 100 new innovations each year.
The Office of Technology Transfer (OTT), part of the Office of Research and Development, works with the inventive researchers on UMBs campus to protect their ideas through patenting and seeks industry partners to develop these ideas into useful medical products. Real-world examples of medical products originating from research at UMB and licensed to companies by OTT are novel cancer-fighting drugs in development by Gliknik Inc, and a stroke rehabilitation device being sold by Encore Path, Inc.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.